Corcept Therapeutics stock has delivered a 447.7% return over the past 5 years, yet broader valuation checks suggest the shares are not a straightforward bargain at current levels.

• That 447.7% five year gain puts Corcept Therapeutics in the category of stocks where past returns are high enough that pricing mistakes can matter more for new investors.
• Expectations around the durability of Corcept Therapeutics' revenue and cash flow, alongside any shift in how investors view its clinical and regulatory risks, can have a meaningful impact on what investors are willing to pay for the stock.
• The company scores just 1 out of 6 on the valuation checks, which leans more toward expensive than clearly undervalued, even though a multiples-based screen suggests there may be upside.

The question for investors is whether Corcept Therapeutics' recent gains leave enough valuation support for those looking at the stock today rather than five years ago.

Is Corcept Therapeutics Still Cheap on Sales?

P/S is often a useful cross check for drug developers like Corcept Therapeutics because revenue can arrive well before earnings look smooth on a P/E basis.

Corcept Therapeutics currently trades on a P/S of 14.9x, which is much higher than the Pharmaceuticals industry average of 5.0x and also above the broader peer group average of 5.4x. On simple comparison, investors are paying a sizeable premium in sales terms for Corcept stock relative to many other listed drug companies.

The valuation model here suggests a “fair” P/S ratio of 17.6x for Corcept Therapeutics once its margins, business profile and risks are factored in. That fair ratio sits above the present 14.9x multiple. This suggests there may be some room for the current share price to move toward what the model treats as a more tailored sales based valuation anchor.

On this P/S framework, Corcept Therapeutics stock appears inexpensive relative to the fair multiple implied by its fundamentals.

The Corcept Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Corcept Therapeutics pick up where the valuation puzzle leaves off. They set out the specific growth, margin and earnings paths that would need to hold for Corcept Therapeutics' stock to be worth materially more or less than today's price, and they sit on Simply Wall St's Community page. Where a single ratio or model gives one number, these narratives explain the future that number depends on so you can watch how it unfolds over time.

Community views on Corcept Therapeutics sit far apart, with one side focused on pipeline upside and the other on execution and legal risk.

Bull case: 5% undervalued

"Impending FDA decisions for relacorilant in hypercortisolism and platinum resistant ovarian cancer, alongside a European approval process, create a visible path to multiple new product launches…"

Bear case: 129% overvalued

"Net income has declined materially despite strong top line growth, with third quarter 2025 revenue rising to $207.6 million while net income fell to $19.7 million compared to $47.2 million last year…"

Do you think there's more to the story for Corcept Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

For Corcept Therapeutics, the current P/S based work points to an undervalued stock on a tailored multiple, even though the broader valuation checks look weak. That split reflects how a single sales based signal can flag potential upside while a wider set of metrics keeps the overall case cautious. The crux for you is whether Corcept Therapeutics can sustain the revenue and margin profile that would justify a premium P/S in light of its clinical, regulatory and legal risks. The answer to that question is what will decide whether the present valuation is a genuine opportunity or a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.